What is the investment case, and what must be true for it to hold?
Immutep can advance eftilagimod alfa into registration-directed development because the Phase II EFTISARC-NEO trial met its primary endpoint, with median tumour hyalinisation or fibrosis of 51.5% across 38 patients against a 35% target, and the company ended the quarter with A$48.50 million in cash and term deposits, funding operations well into the first half of 2028. The thesis holds only provided the manufacturing correction restores the efti profile seen in earlier studies.
Immutep has directed future registration-directed studies of eftilagimod alfa toward head and neck squamous cell carcinoma in PD-L1-negative patients and the neoadjuvant setting of soft tissue sarcoma.
Immutep shares fell 88.6% to A$0.045 after the Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial at a planned interim futility analysis.
The ongoing root cause analysis after the TACTI-004 discontinuation found structural differences between the 2000 L efti batch used in TACTI-004 and the 200 L batch used in earlier successful clinical studies, and a new manufacturing run of efti at 200 L scale has been contracted.
Immutep
Immutep is a late clinical-stage biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune patients.